# MVASI® (bevacizumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/bevacizumab

> The FDA approved MVASI® (bevacizumab), sponsored by Outlook Therapeutics, Inc. (OTLK), on July 24, 2026 for to treat patients with neovascular (wet) age-related macular degeneration.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is MVASI® (bevacizumab) FDA approved?

Yes. The FDA approved MVASI® (bevacizumab), sponsored by Outlook Therapeutics, Inc. (OTLK), on July 24, 2026 for to treat patients with neovascular (wet) age-related macular degeneration. FDA novel drug approvals: "Lytenava | bevacizumab-vikg | 7/24/2026 | To treat patients with neovascular (wet) age-related macular degeneration" [Calendar and source filings](https://sec-api.dev/pdufa/bevacizumab)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/bevacizumab#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | MVASI® (bevacizumab) |
| Codes | ONS-5010 |
| Sponsor | Outlook Therapeutics, Inc. (OTLK) https://sec-api.dev/companies/otlk/catalysts |
| Indications | [wet amd](https://sec-api.dev/indications/wet-amd), retina diseases, today, retinal diseases, today, Ras-mutated Metastatic Colorectal Cancer, [Age-Related Macular Degeneration](https://sec-api.dev/indications/age-related-macular-degeneration), To treat patients with neovascular (wet) age-related macular degeneration |
| Modality | antibody |
| FDA designations | fast track, priority review |

## Timeline

### Aug 2021: topline data readout

- Status: completed, met. Date confidence: month.
- First seen 2024-12-27, last confirmed 2024-12-27.
- SEC Form 10-K (accession 0001558370-24-016491): "The topline results reported from NORSE TWO in August 2021 showed that ONS-5010/LYTENAVA met the primary and key secondary endpoints for efficacy with clinically impactful change observed for treated patients." https://www.sec.gov/Archives/edgar/data/1649989/000155837024016491/otlk-20240930x10k.htm
- SEC Form 10-K (accession 0001558370-24-016491): "The topline results reported from NORSE TWO in August 2021 showed that ONS-5010/LYTENAVA met the primary and key secondary endpoint for efficacy with clinically impactful change observed for treated patients." https://www.sec.gov/Archives/edgar/data/1649989/000155837024016491/otlk-20240930x10k.htm

### Mar 2022: NDA/BLA submission

- Status: completed. Date confidence: month. Indication: wet AMD.
- First seen 2024-12-27, last confirmed 2025-12-19.
- SEC Form 10-K (accession 0001104659-25-123264): "Separately, in March 2022, we submitted a BLA to the FDA for ONS-5010/LYTENAVA for the treatment of wet AMD." https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm
- SEC Form 10-Q (accession 0001558370-25-011588): "Separately, in March 2022, we submitted a BLA with the FDA for ONS-5010/LYTENAVA for the treatment of wet AMD." https://www.sec.gov/Archives/edgar/data/1649989/000155837025011588/otlk-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007873): "Separately, in March 2022, we submitted a BLA with the FDA for ONS-5010/LYTENAVA for the treatment of wet AMD." https://www.sec.gov/Archives/edgar/data/1649989/000155837025007873/otlk-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-24-016491): "Separately, in March 2022, we submitted a BLA with the U.S. Food and Drug Association, or the FDA, for ONS-5010/LYTENAVA™." https://www.sec.gov/Archives/edgar/data/1649989/000155837024016491/otlk-20240930x10k.htm

### April 13, 2022: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2024-11-12, last confirmed 2025-02-28.
- SEC Form 10-K (accession 0001723128-25-000012): "On April 13, 2022, the FDA approved our biologics license application for bevacizumab-maly, a biosimilar referencing Avastin®." https://www.sec.gov/Archives/edgar/data/1723128/000172312825000012/amrx-20241231.htm
- SEC Form 10-K (accession 0001723128-25-000012): "On April 13, 2022, the Food and Drug Administration ("FDA") approved the Company's biologics license application for bevacizumab-maly, a biosimilar referencing Avastin®." https://www.sec.gov/Archives/edgar/data/1723128/000172312825000012/amrx-20241231.htm
- SEC Form 10-Q (accession 0001723128-24-000042): "On April 13, 2022, the FDA approved the Company's biologics license application for bevacizumab-maly, a biosimilar referencing Avastin®." https://www.sec.gov/Archives/edgar/data/1723128/000172312824000042/amrx-20240930.htm

### Aug 2022: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2025-12-19, last confirmed 2025-12-19.
- SEC Form 10-K (accession 0001104659-25-123264): "We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA in August 2022 and in August 2023, we received a CRL in which the FDA concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence." https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm
- SEC Form 10-K (accession 0001104659-25-123264): "We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA in August 2022 and in August2023, we received a CRL in which the FDA concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence." https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm

### Aug 2022: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: month.
- First seen 2025-12-19, last confirmed 2025-12-19.
- SEC Form 10-K (accession 0001104659-25-123264): "We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA in August 2022 and in August 2023, we received a CRL in which the FDA concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence." https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm
- SEC Form 10-K (accession 0001104659-25-123264): "We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA in August 2022 and in August2023, we received a CRL in which the FDA concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence." https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm

### August 30, 2022: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2024-12-27, last confirmed 2025-12-19.
- SEC Form 10-Q (accession 0001558370-25-011588): "We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA on August 30, 2022, and in October 2022, we received confirmation from the FDA that our BLA had been accepted for filing with a goal date of August 29, 2023 for a review decision by the FDA." https://www.sec.gov/Archives/edgar/data/1649989/000155837025011588/otlk-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007873): "We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA on August 30, 2022, and in October 2022, we received confirmation from the FDA that our BLA had been accepted for filing with a goal date of August 29, 2023 for a review decision by the FDA." https://www.sec.gov/Archives/edgar/data/1649989/000155837025007873/otlk-20250331x10q.htm
- SEC Form 10-Q (accession 0001558370-25-001022): "We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA on August 30, 2022, and in October 2022, we received confirmation from the FDA that our BLA had been accepted for filing with a goal date of August 29, 2023 for a review decision by the FDA." https://www.sec.gov/Archives/edgar/data/1649989/000155837025001022/otlk-20241231x10q.htm
- SEC Form 10-K (accession 0001558370-24-016491): "We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA on August 30, 2022, and in October 2022, we received confirmation from the FDA that our BLA had been accepted for filing with a goal date of August 29, 2023 for a review decision by the FDA." https://www.sec.gov/Archives/edgar/data/1649989/000155837024016491/otlk-20240930x10k.htm
- SEC Form 10-K (accession 0001104659-25-123264): "We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA in August 2022, and in October 2022, we received confirmation from the FDA that our BLA had been accepted for filing." https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm

### Aug 2023: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2026-03-16, last confirmed 2026-03-16.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-028103): "We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA in August 2022 and in August 2023, we received a CRL in which the FDA concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence." https://www.sec.gov/Archives/edgar/data/1649989/000110465926028103/tm268874d1_ex99-1.htm

### August 29, 2023: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2024-12-27, last confirmed 2026-08-14.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-028103): "We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA in August 2022 and in August 2023, we received a CRL in which the FDA concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence." https://www.sec.gov/Archives/edgar/data/1649989/000110465926028103/tm268874d1_ex99-1.htm
- SEC prospectus (424B) (accession 0001104659-26-096504): "On August 29, 2023, we received a Complete Response Letter, or CRL, in which the FDA concluded it could not approve our BLA during this review cycle due to several chemical, manufacturing and control, or CMC, issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence." https://www.sec.gov/Archives/edgar/data/1649989/000110465926096504/tm2622281-2_424b5.htm
- SEC prospectus (424B) (accession 0001104659-26-094970): "On August 29, 2023, we received a Complete Response Letter, or CRL, in which the FDA concluded it could not approve our BLA during this review cycle due to several chemical, manufacturing and control, or CMC, issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence." https://www.sec.gov/Archives/edgar/data/1649989/000110465926094970/tm2622281-1_424b5.htm
- SEC prospectus (424B) (accession 0001104659-26-067917): "On August 29, 2023, we received a Complete Response Letter, or CRL, in which the FDA concluded it could not approve our BLA during this review cycle due to several chemical, manufacturing and control, or CMC, issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence." https://www.sec.gov/Archives/edgar/data/1649989/000110465926067917/tm2615976d1_424b5.htm
- SEC Form 10-K (accession 0001104659-25-123264): "On August 29, 2023, we received a CRL in which the FDA concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence." https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm
- SEC Form 10-Q (accession 0001558370-25-011588): "On August 29, 2023, we received a Complete Response Letter, or CRL, in which the FDA concluded it could not approve the BLA during this review cycle due to several chemical, manufacturing and control, or CMC, issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence." https://www.sec.gov/Archives/edgar/data/1649989/000155837025011588/otlk-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011588): "On August 29, 2023, we received a CRL in which the FDA concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence." https://www.sec.gov/Archives/edgar/data/1649989/000155837025011588/otlk-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007873): "On August 29, 2023, we received a Complete Response Letter, or CRL, in which the FDA concluded it could not approve the BLA during this review cycle due to several chemical, manufacturing and control, or CMC, issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence." https://www.sec.gov/Archives/edgar/data/1649989/000155837025007873/otlk-20250331x10q.htm
- SEC Form 10-Q (accession 0001558370-25-001022): "On August 29, 2023, we received a Complete Response Letter, or CRL, in which the FDA concluded it could not approve the BLA during this review cycle due to several chemical, manufacturing and control, or CMC, issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence." https://www.sec.gov/Archives/edgar/data/1649989/000155837025001022/otlk-20241231x10q.htm
- SEC Form 10-K (accession 0001558370-24-016491): "On August 29, 2023, we received a Complete Response Letter, or CRL, in which the FDA concluded it could not approve the BLA during this review cycle due to several chemical, manufacturing and control, or CMC, issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence." https://www.sec.gov/Archives/edgar/data/1649989/000155837024016491/otlk-20240930x10k.htm
- SEC Form 10-K (accession 0001558370-24-016491): "On August 29, 2023, we received a CRL in which the FDA concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence." https://www.sec.gov/Archives/edgar/data/1649989/000155837024016491/otlk-20240930x10k.htm
- SEC Form 10-K (accession 0001558370-24-016491): "On August 29, 2023, we received a Complete Response Letter, or CRL, in which the FDA concluded it could not approve the BLA during this review cycle due to several chemical, manufacturing and control, or CMC, issues, open observations from pre-approval manufacturing inspections, and a lack" https://www.sec.gov/Archives/edgar/data/1649989/000155837024016491/otlk-20240930x10k.htm

### August 29, 2023: PDUFA date

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2024-12-27, last confirmed 2025-02-14.
- SEC Form 10-Q (accession 0001558370-25-001022): "We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA on August 30, 2022, and in October 2022, we received confirmation from the FDA that our BLA had been accepted for filing with a goal date of August 29, 2023 for a review decision by the FDA." https://www.sec.gov/Archives/edgar/data/1649989/000155837025001022/otlk-20241231x10q.htm
- SEC Form 10-K (accession 0001558370-24-016491): "We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA on August 30, 2022, and in October 2022, we received confirmation from the FDA that our BLA had been accepted for filing with a goal date of August 29, 2023 for a review decision by the FDA." https://www.sec.gov/Archives/edgar/data/1649989/000155837024016491/otlk-20240930x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-028103): "We re-submitted the BLA to the FDA for ONS-5010/LYTENAVA in August 2022 and in August 2023, we received a CRL in which the FDA concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence." https://www.sec.gov/Archives/edgar/data/1649989/000110465926028103/tm268874d1_ex99-1.htm

### Dec 2023: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2024-12-27, last confirmed 2026-08-14.
- SEC prospectus (424B) (accession 0001104659-26-096504): "In December 2023, we submitted a Special Protocol Assessment, or SPA, to the FDA for this study (NORSE EIGHT) seeking confirmation that, if successful, it will address the FDA's requirement for a second adequate and well-controlled clinical trial to support our planned resubmission of the ONS-5010 BLA." https://www.sec.gov/Archives/edgar/data/1649989/000110465926096504/tm2622281-2_424b5.htm
- SEC prospectus (424B) (accession 0001104659-26-094970): "In December 2023, we submitted a Special Protocol Assessment, or SPA, to the FDA for this study (NORSE EIGHT) seeking confirmation that, if successful, it will address the FDA's requirement for a second adequate and well-controlled clinical trial to support our planned resubmission of the ONS-5010 BLA." https://www.sec.gov/Archives/edgar/data/1649989/000110465926094970/tm2622281-1_424b5.htm
- SEC prospectus (424B) (accession 0001104659-26-067917): "In December 2023, we submitted a Special Protocol Assessment, or SPA, to the FDA for this study (NORSE EIGHT) seeking confirmation that, if successful, it would address the FDA's requirement for a second adequate and well-controlled clinical trial to support our planned resubmission of the ONS-5010/LYTENAVA BLA." https://www.sec.gov/Archives/edgar/data/1649989/000110465926067917/tm2615976d1_424b5.htm
- SEC prospectus (424B) (accession 0001104659-26-067917): "In December 2023, we submitted a Special Protocol Assessment, or SPA, to the FDA for this study (NORSE EIGHT) seeking confirmation that, if successful, it will address the FDA's requirement for a second adequate and well-controlled clinical trial to support our planned resubmission of the ONS-5010 BLA." https://www.sec.gov/Archives/edgar/data/1649989/000110465926067917/tm2615976d1_424b5.htm
- SEC Form 10-Q (accession 0001104659-26-062632): "In December 2023, we submitted a Special Protocol Assessment, or SPA, to the FDA for this study (NORSE EIGHT) seeking confirmation that, if successful, it would address the FDA's requirement for a second adequate and well-controlled clinical trial to support our planned resubmission of the ONS-5010/LYTENAVA BLA." https://www.sec.gov/Archives/edgar/data/1649989/000110465926062632/otlk-20260331x10q.htm
- SEC Form 10-Q (accession 0001104659-26-016554): "In December 2023, we submitted a Special Protocol Assessment, or SPA, to the FDA for this study (NORSE EIGHT) seeking confirmation that, if successful, it would address the FDA's requirement for a second adequate and well-controlled clinical trial to support our planned resubmission of the ONS-5010/LYTENAVA BLA." https://www.sec.gov/Archives/edgar/data/1649989/000110465926016554/otlk-20251231x10q.htm
- SEC Form 10-K (accession 0001104659-25-123264): "In December 2023, we submitted a Special Protocol Assessment, or SPA, to the FDA for this study (NORSE EIGHT) seeking confirmation that, if successful, it would address the FDA's requirement for a second adequate and well-controlled clinical trial to support our planned resubmission of the ONS-5010/LYTENAVA BLA." https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm
- SEC Form 10-Q (accession 0001558370-25-011588): "In December 2023, the Company submitted a Special Protocol Assessment ("SPA") to the FDA for this study (NORSE EIGHT) seeking confirmation that, if successful, it will address the FDA's requirement for a second adequate and well-controlled clinical trial to support its planned resubmission of the ONS-5010/LYTENAVA BLA." https://www.sec.gov/Archives/edgar/data/1649989/000155837025011588/otlk-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011588): "In December 2023, we submitted a Special Protocol Assessment, or SPA, to the FDA for this study (NORSE EIGHT) seeking confirmation that, if successful, it will address the FDA's requirement for a second adequate and well-controlled clinical trial to support our planned resubmission of the ONS-5010/LYTENAVA BLA." https://www.sec.gov/Archives/edgar/data/1649989/000155837025011588/otlk-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007873): "In December 2023, the Company submitted a Special Protocol Assessment ("SPA") to the FDA for this study (NORSE EIGHT) seeking confirmation that, if successful, it will address the FDA's requirement for a second adequate and well-controlled clinical trial to support its planned resubmission of the ONS-5010/LYTENAVA BLA." https://www.sec.gov/Archives/edgar/data/1649989/000155837025007873/otlk-20250331x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007873): "In December 2023, we submitted a Special Protocol Assessment, or SPA, to the FDA for this study (NORSE EIGHT) seeking confirmation that, if successful, it will address the FDA's requirement for a second adequate and well-controlled clinical trial to support our planned resubmission of the ONS-5010/LYTENAVA BLA." https://www.sec.gov/Archives/edgar/data/1649989/000155837025007873/otlk-20250331x10q.htm
- SEC Form 10-Q (accession 0001558370-25-001022): "In December 2023, the Company submitted a Special Protocol Assessment ("SPA") to the FDA for this study (NORSE EIGHT) seeking confirmation that, if successful, it will address the FDA's requirement for a second adequate and well-controlled clinical trial to support its planned resubmission of the ONS-5010/LYTENAVA BLA." https://www.sec.gov/Archives/edgar/data/1649989/000155837025001022/otlk-20241231x10q.htm

### Jan 2024: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: month.
- First seen 2024-12-27, last confirmed 2025-08-14.
- SEC Form 10-Q (accession 0001558370-25-011588): "In January 2024, the Company received confirmation that the FDA had reviewed and agreed upon the NORSE EIGHT trial protocol pursuant to the SPA and that, if the NORSE EIGHT trial is successful, it would satisfy the FDA's requirement for a second adequate and well-controlled clinical trial to address fully the clinical deficiency identified in the Complete Response Letter ("CRL")." https://www.sec.gov/Archives/edgar/data/1649989/000155837025011588/otlk-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007873): "In January 2024, the Company received confirmation that the FDA had reviewed and agreed upon the NORSE EIGHT trial protocol pursuant to the SPA and that, if the NORSE EIGHT trial is successful, it would satisfy the FDA's requirement for a second adequate and well-controlled clinical trial to address fully the clinical deficiency identified in the Complete Response Letter ("CRL")." https://www.sec.gov/Archives/edgar/data/1649989/000155837025007873/otlk-20250331x10q.htm
- SEC Form 10-Q (accession 0001558370-25-001022): "In January 2024, the Company received confirmation that the FDA had reviewed and agreed upon the NORSE EIGHT trial protocol pursuant to the SPA and that, if the NORSE EIGHT trial is successful, it would satisfy the FDA's requirement for a second adequate and well-controlled clinical trial to address fully the clinical deficiency identified in the Complete Response Letter ("CRL")." https://www.sec.gov/Archives/edgar/data/1649989/000155837025001022/otlk-20241231x10q.htm
- SEC Form 10-K (accession 0001558370-24-016491): "In January 2024, the Company received confirmation that the FDA had reviewed and agreed upon the NORSE EIGHT trial protocol pursuant to the SPA and that, if the NORSE EIGHT trial is successful, it would satisfy the FDA's requirement for a second adequate and well-controlled clinical trial to address fully the clinical deficiency identified in the Complete Response Letter ("CRL")." https://www.sec.gov/Archives/edgar/data/1649989/000155837024016491/otlk-20240930x10k.htm

### 1H 2025: interim data readout

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2024-11-13, last confirmed 2024-11-13.
- SEC Form 10-Q (accession 0000950170-24-126407): "In addition, we are enrolling patients in the expansion phase of the bevacizumab combination Phase 1b study and expect to present initial data from this trial in in the first half of 2025." https://www.sec.gov/Archives/edgar/data/1382101/000095017024126407/stro-20240930.htm

### Q1 2025: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2024-11-27, last confirmed 2025-02-14.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-013509): "Outlook Therapeutics plans to resubmit the BLA for ONS-5010 in the first quarter of calendar 2025." https://www.sec.gov/Archives/edgar/data/1649989/000110465925013509/tm256608d1_ex99-1.htm
- SEC Form 8-K (accession 0001104659-25-004159): "Based on the completed analysis of the 12-week results, the Company plans to resubmit the Biologics License Application ("BLA") for ONS-5010 in the first quarter of calendar 2025." https://www.sec.gov/Archives/edgar/data/1649989/000110465925004159/tm253522d1_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-24-123554): "Upon the completion of analysis of the final results of NORSE EIGHT, Outlook Therapeutics plans to resubmit the Biologics License Application (BLA) application for ONS-5010 in the first quarter of calendar 2025." https://www.sec.gov/Archives/edgar/data/1649989/000110465924123554/tm2429443d1_ex99-1.htm
- SEC Form 10-K (accession 0001558370-24-016491): "Upon receipt of the full month 3 efficacy and safety results for NORSE EIGHT, we plan to resubmit the BLA application for ONS-5010/LYTENAVA in the first quarter of calendar 2025." https://www.sec.gov/Archives/edgar/data/1649989/000155837024016491/otlk-20240930x10k.htm
- SEC Form 10-K (accession 0001558370-24-016491): "Upon receipt of the full month 3 efficacy and safety results for NORSE EIGHT, we plan to resubmit the BLA application for ONS-5010/LYTENAVA in the first quarter of calendar 2025 (see "-Overview")." https://www.sec.gov/Archives/edgar/data/1649989/000155837024016491/otlk-20240930x10k.htm

### February 14, 2025: earnings report

- Status: completed. Date confidence: exact.
- First seen 2025-02-14, last confirmed 2025-02-14.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-013509): "Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced financial results for the first quarter of fiscal year 2025 and provided a corporate update." https://www.sec.gov/Archives/edgar/data/1649989/000110465925013509/tm256608d1_ex99-1.htm

### February 27, 2025: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2025-12-19, last confirmed 2026-03-16.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-028103): "Upon receipt of the full month 3 efficacy and safety results for NORSE EIGHT, we resubmitted the BLA application for ONS-5010/LYTENAVA on February 27, 2025 and received a CRL on August 28, 2025." https://www.sec.gov/Archives/edgar/data/1649989/000110465926028103/tm268874d1_ex99-1.htm
- SEC Form 10-K (accession 0001104659-25-123264): "Upon receipt of the full month 3 efficacy and safety results for NORSE EIGHT, we resubmitted the BLA application for ONS-5010/LYTENAVA on February 27, 2025 and received a CRL on August 28, 2025." https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm
- SEC Form 10-K (accession 0001104659-25-123264): "However, we believe that the data from the trial, in total, demonstrated an improvement in vision and the presence of biologic activity, as well as a continued favorable safety profile for ONS-5010/LYTENAVA and we resubmitted the BLA application for ONS-5010/LYTENAVA on February 27, 2025, and received a subsequent CRL on August 27, 2025." https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm
- SEC Form 10-K (accession 0001104659-25-123264): "However, we believe that the data from the trial, in total, demonstrated an improvement in vision and the presence of biologic activity, as well as a continued favorable safety profile for ONS-5010/LYTENAVA, and subsequently resubmitted our BLA in February 2025, and received a CRL in August 2025." https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm

### February 28, 2025: NDA/BLA submission

- Status: completed. Date confidence: exact.
- First seen 2025-02-28, last confirmed 2026-03-16.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-028103): "Upon receipt of the full month 3 efficacy and safety results for NORSE EIGHT, we resubmitted the BLA application for ONS-5010/LYTENAVA on February 27, 2025 and received a CRL on August 28, 2025." https://www.sec.gov/Archives/edgar/data/1649989/000110465926028103/tm268874d1_ex99-1.htm
- SEC Form 8-K (accession 0001104659-25-018717): "On February 28, 2025, Outlook Therapeutics, Inc. announced that it has resubmitted the Biologics License Application for ONS-5010 to the U.S. Food and Drug Administration." https://www.sec.gov/Archives/edgar/data/1649989/000110465925018717/tm257885d1_8k.htm
- SEC Form 10-K (accession 0001104659-25-123264): "Upon receipt of the full month 3 efficacy and safety results for NORSE EIGHT, we resubmitted the BLA application for ONS-5010/LYTENAVA on February 27, 2025 and received a CRL on August 28, 2025." https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm
- SEC Form 10-K (accession 0001104659-25-123264): "However, we believe that the data from the trial, in total, demonstrated an improvement in vision and the presence of biologic activity, as well as a continued favorable safety profile for ONS-5010/LYTENAVA and we resubmitted the BLA application for ONS-5010/LYTENAVA on February 27, 2025, and received a subsequent CRL on August 27, 2025." https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm
- SEC Form 10-K (accession 0001104659-25-123264): "However, we believe that the data from the trial, in total, demonstrated an improvement in vision and the presence of biologic activity, as well as a continued favorable safety profile for ONS-5010/LYTENAVA, and subsequently resubmitted our BLA in February 2025, and received a CRL in August 2025." https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm

### August 27, 2025: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact. Indication: wet AMD.
- First seen 2025-09-02, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761320_20250827.pdf%22
- Press release filed with the SEC (EX-99) (accession 0001104659-25-086428): "N.J., August 28, 2025 — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) to its biologics license application (BLA) resubmission, indicating that the FDA cannot approve the application in its present form for the treatment of wet age-related macular degeneration (wet AMD)." https://www.sec.gov/Archives/edgar/data/1649989/000110465925086428/tm2524956d1_ex99-1.htm
- SEC Form 8-K (accession 0001104659-25-094558): "Inc (the "Company") issued a press release announcing that it has completed the requested Type A Meeting with the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) dated August 27, 2025 regarding the biologics license application (BLA) resubmission for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD." https://www.sec.gov/Archives/edgar/data/1649989/000110465925094558/tm2527376d1_8k.htm
- SEC Form 8-K (accession 0001104659-25-086428): "On August 28, 2025, Outlook Therapeutics, Inc (the "Company") issued a press release announcing that the U.S. Food and Drug Administration issued a complete response letter to the Company's biologics license application for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD." https://www.sec.gov/Archives/edgar/data/1649989/000110465925086428/tm2524956d1_8k.htm
- SEC prospectus (424B) (accession 0001104659-26-067917): "On August 27, 2025, we received a second CRL from the FDA." https://www.sec.gov/Archives/edgar/data/1649989/000110465926067917/tm2615976d1_424b5.htm
- SEC Form 10-Q (accession 0001104659-26-062632): "On August 27, 2025, we received a second CRL from the FDA." https://www.sec.gov/Archives/edgar/data/1649989/000110465926062632/otlk-20260331x10q.htm
- SEC Form 10-Q (accession 0001104659-26-016554): "On August 27, 2025, we received a second CRL from the FDA." https://www.sec.gov/Archives/edgar/data/1649989/000110465926016554/otlk-20251231x10q.htm
- SEC Form 10-K (accession 0001104659-25-123264): "On August 27, 2025, we received a second CRL from the FDA." https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm

### August 27, 2025: PDUFA date

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2025-05-15, last confirmed 2025-08-14.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-078622): "U.S. Food and Drug Administration (FDA) PDUFA goal date for ONS-5010 is August 27, 2025." https://www.sec.gov/Archives/edgar/data/1649989/000110465925078622/tm2523462d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-049411): "Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in the United States" https://www.sec.gov/Archives/edgar/data/1649989/000110465925049411/tm2515284d1_ex99-1.htm
- SEC Form 10-Q (accession 0001558370-25-011588): "In April 2025, the Company received notification from the FDA that the Prescription Drug User Fee Act ("PDUFA") goal date for a decision on the BLA is August 27, 2025." https://www.sec.gov/Archives/edgar/data/1649989/000155837025011588/otlk-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011588): "In April 2025, we received notification from the FDA that the Prescription Drug User Fee Act, or PDUFA, goal date for a decision on the BLA is August 27, 2025." https://www.sec.gov/Archives/edgar/data/1649989/000155837025011588/otlk-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007873): "In April 2025, the Company received notification from the FDA that the Prescription Drug User Fee Act ("PDUFA") goal date for a decision on the BLA is August 27, 2025." https://www.sec.gov/Archives/edgar/data/1649989/000155837025007873/otlk-20250331x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007873): "In April 2025, we received notification from the FDA that the Prescription Drug User Fee Act, or PDUFA, goal date for a decision on the BLA is August 27, 2025." https://www.sec.gov/Archives/edgar/data/1649989/000155837025007873/otlk-20250331x10q.htm
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761320_20250827.pdf%22

### Sep 2025: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2025-12-19, last confirmed 2026-05-29.
- SEC Form 10-K (accession 0001104659-25-123264): "Following a September 2025 Type A meeting with the FDA, we resubmitted the ONS-5010/LYTENAVA BLA and have received a Prescription Drug User Fee Act, or PDUFA, goal date of December 31, 2025 for a decision by the FDA." https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm
- SEC Form 10-K (accession 0001104659-25-123264): "Following a September 2025 Type A meeting with the FDA, we resubmitted the ONS-5010/LYTENAVA BLA on November 3, 2025 and received a PDUFA goal date of December 31, 2025 from the FDA." https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm
- SEC prospectus (424B) (accession 0001104659-26-067917): "Following a September 2025 Type A meeting with the FDA, we resubmitted the BLA in October 2025." https://www.sec.gov/Archives/edgar/data/1649989/000110465926067917/tm2615976d1_424b5.htm
- SEC Form 10-Q (accession 0001104659-26-062632): "Following a September 2025 Type A meeting with the FDA, we resubmitted the BLA in October 2025." https://www.sec.gov/Archives/edgar/data/1649989/000110465926062632/otlk-20260331x10q.htm
- SEC Form 10-Q (accession 0001104659-26-016554): "Following a September 2025 Type A meeting with the FDA, we resubmitted the BLA in October 2025." https://www.sec.gov/Archives/edgar/data/1649989/000110465926016554/otlk-20251231x10q.htm

### November 3, 2025: NDA/BLA submission

- Status: completed. Date confidence: exact. Indication: retina diseases, today.
- First seen 2025-11-03, last confirmed 2026-03-16.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-028103): "On November 3, 2025 we resubmitted the ONS-5010/LYTENAVA BLA and on December" https://www.sec.gov/Archives/edgar/data/1649989/000110465926028103/tm268874d1_ex99-1.htm
- SEC Form 10-K (accession 0001104659-25-123264): "On November 3, 2025 we resubmitted the ONS-5010/LYTENAVA BLA and have received a PDUFA goal date of December 31, 2025 for a decision by the FDA." https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-105633): "N.J., November 3, 2025 — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has re-submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010, after receiving the official minutes from the FDA Type A meeting conducted in September 2025." https://www.sec.gov/Archives/edgar/data/1649989/000110465925105633/tm2530088d1_ex99-1.htm

### December 30, 2025: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact. Indication: wet AMD.
- First seen 2026-01-02, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761320_20251230.pdf%22
- SEC Form 10-Q (accession 0001104659-26-062632): "Moreover, on December 31, 2025, we reported that we had received a third CRL with respect to our BLA for ONS-5010, and the FDA has again recommended that confirmatory evidence of efficacy be submitted to support the application." https://www.sec.gov/Archives/edgar/data/1649989/000110465926062632/otlk-20260331x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-028103): "Moreover, on December 31, 2025, we reported that we had received a third Complete Response Letter, or CRL, with respect to our Biologics" https://www.sec.gov/Archives/edgar/data/1649989/000110465926028103/tm268874d1_ex99-1.htm
- SEC Form 8-K (accession 0001104659-26-000066): "On December 31, 2025, Outlook Therapeutics, Inc (the "Company") issued a press release announcing that the U.S. Food and Drug Administration issued a complete response letter to the Company's biologics license application for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD." https://www.sec.gov/Archives/edgar/data/1649989/000110465926000066/tm2534608d1_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-000066): "— Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) to the ONS-5010/LYTENAVA ™ (bevacizumab-vikg) biologics license application (BLA)" https://www.sec.gov/Archives/edgar/data/1649989/000110465926000066/tm2534608d1_ex99-1.htm
- SEC Form 10-Q (accession 0001104659-26-062632): "On December 31, 2025, we reported that we had received a third CRL in which the FDA noted that the additional mechanistic and natural history data information provided in the BLA resubmission does not alter the previous review conclusion that while the one adequate and well-controlled study demonstrated efficacy, and the FDA has again recommended that confirmatory evidence of efficacy be submitted to support the application." https://www.sec.gov/Archives/edgar/data/1649989/000110465926062632/otlk-20260331x10q.htm
- SEC Form 10-Q (accession 0001104659-26-016554): "On December 31, 2025, we reported that we had received a third CRL in which the FDA noted that the additional mechanistic and natural history data information provided in the BLA resubmission does not alter the previous review conclusion that while the one adequate and well-controlled study demonstrated efficacy, and the FDA has again recommended that confirmatory evidence of efficacy be submitted to support the application." https://www.sec.gov/Archives/edgar/data/1649989/000110465926016554/otlk-20251231x10q.htm

### December 31, 2025: NDA/BLA submission

- Status: completed. Date confidence: exact.
- First seen 2026-02-17, last confirmed 2026-05-15.
- SEC Form 10-Q (accession 0001104659-26-062632): "On December 31, 2025, we reported that we had received a third CRL in which the FDA noted that the additional mechanistic and natural history data information provided in the BLA resubmission does not alter the previous review conclusion that while the one adequate and well-controlled study demonstrated efficacy, and the FDA has again recommended that confirmatory evidence of efficacy be submitted to support the application." https://www.sec.gov/Archives/edgar/data/1649989/000110465926062632/otlk-20260331x10q.htm
- SEC Form 10-Q (accession 0001104659-26-016554): "On December 31, 2025, we reported that we had received a third CRL in which the FDA noted that the additional mechanistic and natural history data information provided in the BLA resubmission does not alter the previous review conclusion that while the one adequate and well-controlled study demonstrated efficacy, and the FDA has again recommended that confirmatory evidence of efficacy be submitted to support the application." https://www.sec.gov/Archives/edgar/data/1649989/000110465926016554/otlk-20251231x10q.htm

### December 31, 2025: PDUFA date

- Status: completed, complete response letter. Date confidence: exact. Indication: wet AMD.
- First seen 2025-12-19, last confirmed 2025-12-19.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-122786): "Food and Drug Administration (FDA) PDUFA goal date for ONS-5010 is December 31, 2025." https://www.sec.gov/Archives/edgar/data/1649989/000110465925122786/tm2533934d1_ex99-1.htm
- SEC Form 10-K (accession 0001104659-25-123264): "We subsequently resubmitted the ONS-5010/LYTENAVA BLA and have received a Prescription Drug User Fee Act, or PDUFA, goal date of December 31, 2025 for a decision by the FDA;" https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm
- SEC Form 10-K (accession 0001104659-25-123264): "Following a September 2025 Type A meeting with the FDA, we resubmitted the ONS-5010/LYTENAVA BLA and have received a Prescription Drug User Fee Act, or PDUFA, goal date of December 31, 2025 for a decision by the FDA." https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm
- SEC Form 10-K (accession 0001104659-25-123264): "We are actively working towards obtaining FDA approval of ONS-5010/LYTENAVA for the treatment of wet AMD and have received a PDUFA goal date of December 31, 2025 for an FDA decision on our resubmitted BLA." https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm
- SEC Form 10-K (accession 0001104659-25-123264): "On November 3, 2025 we resubmitted the ONS-5010/LYTENAVA BLA and have received a PDUFA goal date of December 31, 2025 for a decision by the FDA." https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm
- SEC Form 10-K (accession 0001104659-25-123264): "Following a September 2025 Type A meeting with the FDA, we resubmitted the ONS-5010/LYTENAVA BLA on November 3, 2025 and received a PDUFA goal date of December 31, 2025 from the FDA." https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761320_20251230.pdf%22

### February 17, 2026: earnings report

- Status: completed. Date confidence: exact.
- First seen 2026-02-17, last confirmed 2026-02-17.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-015887): "(Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced financial results for the first quarter fiscal year 2026 and provided a corporate update." https://www.sec.gov/Archives/edgar/data/1649989/000110465926015887/tm266557d1_ex99-1.htm

### February 20, 2026: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2025-10-30, last confirmed 2025-11-05.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-103974): "FDA Set PDUFA Date of Feb. 20, 2026" https://www.sec.gov/Archives/edgar/data/310158/000110465925103974/tm2529620d1_ex99-1.htm
- SEC Form 10-Q (accession 0000310158-25-000059): "The FDA set a PDUFA date of February 20, 2026." https://www.sec.gov/Archives/edgar/data/310158/000031015825000059/mrk-20250930.htm

### Jun 2026: NDA/BLA submission

- Status: scheduled. Date confidence: month.
- First seen 2026-05-26, last confirmed 2026-05-29.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-065992): "As a result, Outlook Therapeutics expects to resubmit the ONS-5010/LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) in June 2026." https://www.sec.gov/Archives/edgar/data/1649989/000110465926065992/tm2615583d1_ex99-1.htm
- SEC prospectus (424B) (accession 0001104659-26-067917): "As a result, we expect to resubmit the ONS-5010/LYTENAVA™ (bevacizumab-vikg) BLA in June 2026." https://www.sec.gov/Archives/edgar/data/1649989/000110465926067917/tm2615976d1_424b5.htm

### 2H 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2025-05-12, last confirmed 2026-08-05.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-091188): "Enrollment is complete in the randomized Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L uHCC and the first data readout is expected 2H 2026." https://www.sec.gov/Archives/edgar/data/1512762/000110465926091188/chrs-20260805xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-058666): "Enrollment is complete in the randomized Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L uHCC and the first data readout is expected in mid-2026." https://www.sec.gov/Archives/edgar/data/1512762/000110465926058666/chrs-20260511xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-025293): "Enrollment is ongoing in the randomized Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L uHCC, with the first data readout expected in mid-2026." https://www.sec.gov/Archives/edgar/data/1512762/000110465926025293/chrs-20260309xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-107780): "Enrollment is ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with the first data readout expected in mid-2026." https://www.sec.gov/Archives/edgar/data/1512762/000110465925107780/chrs-20251106xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-010802): "Enrollment is ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with the first data readout expected in 1H 2026." https://www.sec.gov/Archives/edgar/data/1512762/000155837025010802/chrs-20250807xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-007410): "- Enrollment ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with first data readout expected in 1H 2026 -" https://www.sec.gov/Archives/edgar/data/1512762/000155837025007410/chrs-20250512xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-007410): "Enrollment is ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with the first data readout expected in 1H 2026." https://www.sec.gov/Archives/edgar/data/1512762/000155837025007410/chrs-20250512xex99d1.htm

### 2H 2026: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-11-05, last confirmed 2026-03-19.
- SEC Form 10-K (accession 0001493152-26-011616): "We anticipate reporting topline results in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1231457/000149315226011616/form10-k.htm
- SEC Form 10-K (accession 0001493152-26-011616): "3 trial with topline results anticipated in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1231457/000149315226011616/form10-k.htm
- SEC Form 10-K (accession 0001493152-26-011616): "We expect to report topline results from the trial in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1231457/000149315226011616/form10-k.htm
- SEC Form 10-Q (accession 0001493152-25-020874): "3 trial with topline results anticipated in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1231457/000149315225020874/form10-q.htm

### July 24, 2026: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat patients with neovascular (wet) age-related macular degeneration.
- First seen 2026-07-24, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Lytenava | bevacizumab-vikg | 7/24/2026 | To treat patients with neovascular (wet) age-related macular degeneration" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
- openFDA Drugs@FDA: "BLA761320 ORIG-1 (Type 1 - New Molecular Entity and Type 4 - New Combination): submission_status AP, submission_status_date 20260724, review_priority STANDARD; sponsor_name OUTLOOK THERAPEUTICS, INC.; product LYTENAVA (BEVACIZUMAB-VIKG)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761320%22
- SEC Form 8-K (accession 0001104659-26-094848): "On July 24, 2026, the Company announced that the U.S. Food and Drug Administration ("FDA") had approved LYTENAVA™ (bevacizumab-vikg)" https://www.sec.gov/Archives/edgar/data/1649989/000110465926094848/tm2622278d1_8k.htm
- SEC Form 10-Q (accession 0001104659-26-098415): "On July 24, 2026 the Company announced FDA approval of LYTENAVATM as the only FDA-approved ophthalmic Bevacizumab for the treatment of Wet AMD." https://www.sec.gov/Archives/edgar/data/1649989/000110465926098415/otlk-20260630x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-086685): "Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved LYTENAVA™ (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration (nAMD), commonly known as wet AMD." https://www.sec.gov/Archives/edgar/data/1649989/000110465926086685/tm2621316d1_ex99-1.htm
- SEC Form 10-Q (accession 0001104659-26-098415): "On July 24, 2026, the FDA approved the Company's biologics license application for LYTENAVA™ (bevacizumab-vikg) for the treatment of wet AMD." https://www.sec.gov/Archives/edgar/data/1649989/000110465926098415/otlk-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-098415): "On July 24, 2026, the FDA approved our biologics license application for LYTENAVA™ (bevacizumab-vikg) for the treatment of wet AMD." https://www.sec.gov/Archives/edgar/data/1649989/000110465926098415/otlk-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-098415): "In July 2026, we received FDA approval for LYTENAVA (bevacizumab-vikg) for the treatment of wet AMD in the United States, which results in 12 years of regulatory exclusivity in the United States." https://www.sec.gov/Archives/edgar/data/1649989/000110465926098415/otlk-20260630x10q.htm

### late 2026: trial start

- Status: scheduled. Date confidence: half. Stage: 1/2.
- First seen 2026-03-16, last confirmed 2026-03-16.
- SEC Form 10-K (accession 0001193125-26-107146): "We also plan to initiate a Phase 1b/2 study or Varseta-M in combination with bevacizumab and chemotherapy by the end of 2026." https://www.sec.gov/Archives/edgar/data/1501989/000119312526107146/ctmx-20251231.htm
- SEC Form 10-K (accession 0001193125-26-107146): "We also plan to initiate a Phase 1b/2 study of Varseta-M in combination with bevacizumab and chemotherapy by the end of 2026." https://www.sec.gov/Archives/edgar/data/1501989/000119312526107146/ctmx-20251231.htm

### 1H 2027: interim data readout

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2026-03-16, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-211920): "1 doses to be assessed in combination with bevacizumab will include Q2W and Q4W schedules to align with the approved bevacizumab CRC dose of 5 mg/kg Q2W. Initial clinical data are anticipated by 1H 2027." https://www.sec.gov/Archives/edgar/data/1501989/000119312526211920/ctmx-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-449739): "Varseta-M doses to be assessed in combination with bevacizumab include Q2W and Q4W schedules to align with the approved bevacizumab CRC dose of 5 mg/kg Q2W. The study continues to enroll, with initial clinical data from this Varseta-M combination with bevacizumab anticipated in the first half of 2027." https://www.sec.gov/Archives/edgar/data/1501989/000119312526449739/ctmx-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-337950): "Varseta-M doses to be assessed in combination with bevacizumab include Q2W and Q4W schedules to align with the approved bevacizumab CRC dose of 5 mg/kg Q2W. The study continues with initial clinical data from the Varseta-M combination with bevacizumab anticipated by the first half of 2027." https://www.sec.gov/Archives/edgar/data/1501989/000119312526337950/ctmx-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-211868): "Varseta-M doses to be assessed in combination with bevacizumab will include Q2W and Q4W schedules to align with the approved bevacizumab CRC dose of 5 mg/kg Q2W. Initial clinical data are anticipated by the first half of 2027." https://www.sec.gov/Archives/edgar/data/1501989/000119312526211868/ctmx-20260331.htm
- SEC Form 10-K (accession 0001193125-26-107146): "Initial data from the combination study with bevacizumab is expected by the first half of 2027." https://www.sec.gov/Archives/edgar/data/1501989/000119312526107146/ctmx-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-449787): "Initial clinical data is anticipated in 1H 2027." https://www.sec.gov/Archives/edgar/data/1501989/000119312526449787/ctmx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-338009): "Initial clinical data is anticipated in 1H 2027." https://www.sec.gov/Archives/edgar/data/1501989/000119312526338009/ctmx-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-449739): "Varseta-M doses to be assessed in combination with bevacizumab include an every-two-week schedule ("Q2W") and an every-four-week schedule ("Q4W") to align with the approved bevacizumab CRC dose and schedule of 5 mg/kg Q2W. The Phase 1 combination study with bevacizumab continues, with initial clinical data anticipated by the first half of 2027." https://www.sec.gov/Archives/edgar/data/1501989/000119312526449739/ctmx-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-337950): "Varseta-M doses to be assessed in combination with bevacizumab include Q2W and Q4W schedules to align with the approved bevacizumab CRC dose and schedule of 5 mg/kg Q2W. The Phase 1 combination study with bevacizumab continues with initial clinical data anticipated by first half of 2027." https://www.sec.gov/Archives/edgar/data/1501989/000119312526337950/ctmx-20260630.htm
- SEC Form 10-K (accession 0001193125-26-107146): "We also are prioritizing the development of Varseta-M into earlier lines of therapy and initiated a Phase 1 combination study with Varseta-M and bevacizumab in the first quarter of 2026 with initial data expected in the first half of 2027." https://www.sec.gov/Archives/edgar/data/1501989/000119312526107146/ctmx-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-211920): "- Varseta-M Phase 1 study evaluating combination with bevacizumab is ongoing with initial data expected by 1H 2027; Phase 1/2 Varseta-M chemotherapy combination study to be initiated in 2H 2026 -" https://www.sec.gov/Archives/edgar/data/1501989/000119312526211920/ctmx-ex99_1.htm

### 1H 2027: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2026-11-09, last confirmed 2026-11-09.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-124511): "Enrollment in the randomized Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L uHCC is complete and the first data readout is expected in 1H 2027." https://www.sec.gov/Archives/edgar/data/1512762/000110465926124511/chrs-ex99d1.htm

### Aug to Nov 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Ras-mutated Metastatic Colorectal Cancer; mCRC; MSS Metastatic Colorectal Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07446322 (FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-30 (ESTIMATED); Lead Sponsor Oncolytics Biotech." https://clinicaltrials.gov/study/NCT07446322

### August 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Ras-mutated Metastatic Colorectal Cancer; mCRC; MSS Metastatic Colorectal Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07446322 (FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-30 (ESTIMATED); Lead Sponsor Oncolytics Biotech." https://clinicaltrials.gov/study/NCT07446322

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05112861 (A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Outlook Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT05112861

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05112861 (A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Outlook Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT05112861

## Same indication

- [Iptacopan (lnp023)](https://sec-api.dev/pdufa/iptacopan-lnp023) (NVS)
- [LYTENAVA™ (lytenava)](https://sec-api.dev/pdufa/lytenava) (OTLK)

Calendar months: [February 2026](https://sec-api.dev/fda-calendar/2026-02), [August 2027](https://sec-api.dev/fda-calendar/2027-08)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/bevacizumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MVASI® (bevacizumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/bevacizumab

```bibtex
@misc{secapidev_pdufa_bevacizumab_20261116,
  title        = {MVASI® (bevacizumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/bevacizumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_bevacizumab_20261116","title":"MVASI® (bevacizumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/bevacizumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
